No. 20-1110

Sandoz Inc., et al. v. Immunex Corporation, et al.

Lower Court: Federal Circuit
Docketed: 2021-02-12
Status: Denied
Type: Paid
Amici (1) Experienced Counsel
Tags: biosimilar-product double-patenting exclusivity federal-circuit invention obviousness obviousness-type-double-patenting patent patent-exclusivity patent-ownership substantial-rights
Key Terms:
Antitrust Patent
Latest Conference: 2021-05-13
Question Presented (AI Summary)

May the patent owner avoid the rule against double patenting by buying all of the substantial rights to a second, later-expiring patent for essentially the same invention, so long as the seller retains nominal ownership and a theoretical secondary right to sue for infringement?

Question Presented (OCR Extract)

QUESTION PRESENTED Under federal patent law, a patent owner may receive only one period of exclusivity for its invention and may not obtain a second patent on the same invention or a “colorable variation” thereof. McCreary v. Pa. Canal Co., 141 U.S. 459, 467 (1891). The question presented is: May the patent owner avoid the rule against double patenting by buying all of the substantial rights to a second, later-expiring patent for essentially the same invention, so long as the seller retains nominal ownership and a theoretical secondary right to sue for infringement? i

Docket Entries

2021-05-17
Petition DENIED.
2021-04-27
DISTRIBUTED for Conference of 5/13/2021.
2021-04-26
Reply of petitioners Sandoz Inc., Sandoz International GmbH, Sandoz GmbH filed. (Distributed)
2021-04-12
Brief of respondents Immunex Corp., et al. in opposition filed.
2021-03-15
Brief amici curiae of Association for Accessible Medicines and America's Health Insurance Plans, Inc. filed.
2021-02-25
Motion to extend the time to file a response is granted and the time is extended to and including April 14, 2021.
2021-02-24
Motion to extend the time to file a response from March 15, 2021 to April 14, 2021, submitted to The Clerk.
2021-01-29
Petition for a writ of certiorari filed. (Response due March 15, 2021)

Attorneys

Association for Accessible Medicines and America's Health Insurance Plans, Inc.
Matthew S. HellmanJenner & Block LLP, Amicus
Matthew S. HellmanJenner & Block LLP, Amicus
Immunex Corp., et al.
Constantine L. Trela Jr.Sidley Austin LLP, Respondent
Constantine L. Trela Jr.Sidley Austin LLP, Respondent
Sandoz Inc., Sandoz International GmbH, Sandoz GmbH
William McGinley JayGoodwin Procter, LLP, Petitioner
William McGinley JayGoodwin Procter, LLP, Petitioner